Creating cell and animal models of human disease by genome editing using CRISPR/Cas9

The Journal of Gene Medicine
Ali ZareiSeyed Mohammad Bagher Tabei

Abstract

A set of unique sequences in bacterial genomes, responsible for protecting bacteria against bacteriophages, has recently been used for the genetic manipulation of specific points in the genome. These systems consist of one RNA component and one enzyme component, known as CRISPR ("clustered regularly interspaced short palindromic repeats") and Cas9, respectively. The present review focuses on the applications of CRISPR/Cas9 technology in the development of cellular and animal models of human disease. Making a desired genetic alteration depends on the design of RNA molecules that guide endonucleases to a favorable genomic location. With the discovery of CRISPR/Cas9 technology, researchers are able to achieve higher levels of accuracy because of its advantages over alternative methods for editing genome, including a simple design, a high targeting efficiency and the ability to create simultaneous alterations in multiple sequences. These factors allow the researchers to apply this technology to creating cellular and animal models of human diseases by knock-in, knock-out and Indel mutation strategies, such as for Huntington's disease, cardiovascular disorders and cancers. Optimized CRISPR/Cas9 technology will facilitate access to va...Continue Reading

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·L LiS Chandrasegaran
Jun 16, 1989·Science·V G PurselR E Hammer
Jan 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·J M Berg
Dec 13, 2000·Molecular and Cellular Biology·M BibikovaS Chandrasegaran
Oct 22, 2004·Nature·UNKNOWN International Human Genome Sequencing Consortium
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Erica A MoehleM C Holmes
Mar 24, 2007·Science·Rodolphe BarrangouPhilippe Horvath
Nov 16, 2007·Proteins·Armando D Solis, S Rackovsky
Jan 30, 2009·Protein Engineering, Design & Selection : PEDS·Zhilei ChenHuimin Zhao
Apr 30, 2009·Annual Review of Phytopathology·Jens Boch, Ulla Bonas
Feb 4, 2010·Nature Reviews. Genetics·Luciano A Marraffini, Erik J Sontheimer
Dec 24, 2010·Nature Biotechnology·Jeffrey C MillerEdward J Rebar
Mar 2, 2012·Nature Reviews. Drug Discovery·Jack W ScannellBrian Warrington
Apr 10, 2012·Nature Biotechnology·Deepak ReyonJ Keith Joung
Jun 30, 2012·Science·Martin JinekEmmanuelle Charpentier
Dec 19, 2012·Cell Stem Cell·Qiurong DingChad A Cowan
Jan 5, 2013·Science·Le CongFeng Zhang
Feb 13, 2013·Proceedings of the National Academy of Sciences of the United States of America·Junhee SeokUNKNOWN Inflammation and Host Response to Injury, Large Scale Collaborative Research Program
Feb 14, 2013·RNA Biology·Shiraz A ShahRoger A Garrett
May 15, 2013·Trends in Biotechnology·Thomas GajCarlos F Barbas
Jun 27, 2013·BMC Medicine·Richard D Baird, Carlos Caldas
Jul 23, 2013·PloS One·Woong Y HwangJing-Ruey Joanna Yeh
Aug 7, 2013·Proceedings of the National Academy of Sciences of the United States of America·Li-En JaoWenbiao Chen
Aug 14, 2013·Proceedings of the National Academy of Sciences of the United States of America·Zhonggang HouJames A Thomson
Aug 21, 2013·Cell Research·Zhengyan FengJian-Kang Zhu
Jan 28, 2014·Nature Biotechnology·Yanfang FuJ Keith Joung
Feb 18, 2014·Cell·Hiroshi NishimasuOsamu Nureki
Mar 29, 2014·Current Gene Therapy·Mi Cai, Yi Yang
Apr 1, 2014·Nature Biotechnology·Hao YinDaniel G Anderson
Jun 12, 2014·Circulation Research·Qiurong DingKiran Musunuru
Jun 24, 2014·Scientific Reports·Masafumi InuiShuji Takada

❮ Previous
Next ❯

Citations

Mar 28, 2020·Genes·Kenji Rowel Q LimToshifumi Yokota
Jun 27, 2020·Animals : an Open Access Journal From MDPI·Ana Carolina Furlanetto MançanaresFidel Ovidio Castro
Sep 4, 2020·Diagnostics·Anca OnaciuIoana Berindan-Neagoe
Sep 24, 2020·Pharmaceutics·Yanfang Wang, Ernst Wagner
Dec 17, 2020·Expert Opinion on Drug Discovery·Laure Grand MourselAnne-Marie Zuurmond
Oct 3, 2020·Computational and Structural Biotechnology Journal·Yuanyuan Xu, Zhanjun Li
Apr 5, 2020·Advanced Drug Delivery Reviews·Franziska Freitag, Ernst Wagner
Jun 19, 2021·Molecular Biology Reports·Kirti PrasadKumarasamypet M Mohankumar
Jun 20, 2021·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Jinfu ZhangShengsong Xie

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR Genome Editing & Therapy

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of this system for gene editing and therapy in human diseases.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.